10-Q: Alkermes Reports Q2 2025 Financials Amidst Royalty Expirations and Strong Proprietary Product Growth

Alkermes plc reported a decrease in overall revenue and net income for Q2 2025 due to expected royalty expirations, while showcasing robust growth in proprietary product sales and advancing its neuroscience pipeline with positive clinical trial results for Alixorexton.

Summary

• Net income from continuing operations for the three months ended June 30, 2025, was $87.1 million ($0.52 diluted EPS), down from $94.7 million ($0.55 diluted EPS) in the prior year period.
• Net income from continuing operations for the six months ended June 30, 2025, was $109.6 million ($0.65 diluted EPS), down from $133.6 million ($0.78 diluted EPS) in the prior year period.
• Total revenues for the three months ended June 30, 2025, decreased to $390.7 million from $399.1 million in the prior year period.
• Total revenues for the six months ended June 30, 2025, decreased to $697.2 million from $749.5 million in the prior year period.
• Product sales, net, increased by $38.0 million to $307.2 million for the three months ended June 30, 2025, and by $49.0 million to $551.7 million for the six months ended June 30, 2025, compared to the prior year periods.
• VIVITROL sales increased to $121.7 million (Q2 2025) and $222.7 million (YTD 2025).
• ARISTADA and ARISTADA INITIO sales increased to $101.3 million (Q2 2025) and $174.8 million (YTD 2025).
• LYBALVI sales increased to $84.3 million (Q2 2025) and $154.3 million (YTD 2025), driven by a 14% increase in units sold for Q2 and 17% for YTD.
• Manufacturing and royalty revenues decreased significantly due to the expiration of the INVEGA SUSTENNA U.S. royalty in August 2024 and the conclusion of FAMPYRA manufacturing obligations.
• Research and development expenses increased by $17.8 million to $77.4 million for Q2 2025 and by $21.9 million to $149.2 million for YTD 2025, primarily due to advancement of the Alixorexton development program.
• Cash and cash equivalents increased to $521.2 million as of June 30, 2025, from $291.1 million at December 31, 2024.
• Cash flows provided by operating activities were $249.0 million for the six months ended June 30, 2025, up from $167.1 million in the prior year period.
• The company has $200.0 million remaining under its share repurchase program as of June 30, 2025, with no repurchases made during the six months ended June 30, 2025.

Sentiment

Score: 6

Explanation: The sentiment is mixed. While overall revenue and net income declined due to expected royalty expirations, proprietary product sales showed strong growth, and the company's cash position improved significantly. Positive clinical trial results for a key pipeline candidate (Alixorexton) and resolution of a major litigation (VUMERITY) are strong positives, indicating strategic progress despite the financial transition.

Positives

• Proprietary product sales (VIVITROL, ARISTADA/INITIO, LYBALVI) showed strong growth, with LYBALVI unit sales increasing by 14% in Q2 and 17% year-to-date.
• Cash and cash equivalents significantly increased to $521.2 million as of June 30, 2025, from $291.1 million at December 31, 2024.
• Cash flows provided by operating activities increased substantially to $249.0 million for the six months ended June 30, 2025, compared to $167.1 million in the prior year period.
• Alixorexton achieved its primary endpoint in the Vibrance-1 study for narcolepsy type 1, leading to plans for a phase 3 program.
• U.S. Patent No. 12,311,027 relating to ARISTADA was granted in May 2025, extending protection until 2033.
• The VUMERITY ANDA litigation was confidentially settled in July 2025, granting a license for a generic version from an agreed date, resolving a significant legal proceeding.

Negatives

• Total revenues decreased by $8.5 million for the three months and $52.3 million for the six months ended June 30, 2025, compared to the prior year periods.
• Net income from continuing operations decreased by $7.6 million for the three months and $24.0 million for the six months ended June 30, 2025, compared to the prior year periods.
• Manufacturing and royalty revenues experienced a significant decline, primarily due to the expiration of the INVEGA SUSTENNA U.S. royalty in August 2024 and the conclusion of FAMPYRA manufacturing obligations.
• VIVITROL unit sales decreased by 1% in Q2 and 3% year-to-date.
• ARISTADA/ARISTADA INITIO unit sales decreased by 3% year-to-date.

Risks

• Uncertainty over intellectual property (IP) in the biopharmaceutical industry can lead to litigation and competition from generic drug manufacturers, as seen with INVEGA TRINZA and VUMERITY.
• Changes in global trade or other policies, including tariffs or other restrictions imposed by governments, could adversely affect business, results of operations, or financial condition, particularly given international supply chain components and potential pharmaceutical import tariffs.
• Drug development involves a high degree of risk and investment, and the status, timing, and scope of development programs are subject to change, potentially impacting future product pipeline success.

Future Outlook

Royalty revenues from long-acting INVEGA products are expected to continue to be lower for the remainder of 2025 due to the expiration of the INVEGA SUSTENNA U.S. royalty. The recently signed One Big Beautiful Bill (OBB Bill) is expected to result in a material increase in cash flows from operating activities and a material decrease in net U.S. deferred tax assets over the next number of years. Existing cash, cash equivalents, and investments are projected to be sufficient to finance anticipated working capital and other cash requirements for at least the next twelve months. The company may pursue additional financing opportunities in the future, including debt and equity offerings, corporate collaborations, or bank borrowings. Following positive Phase 2 results, the company is proceeding with plans for the initiation of a Phase 3 program for Alixorexton in narcolepsy.

Management Comments

• Richard F. Pops, Chairman and Chief Executive Officer, and Blair C. Jackson, Executive Vice President, Chief Operating Officer and Interim Principal Financial Officer, certified that the report fully complies with SEC requirements and fairly presents the financial condition and results of operations.

Industry Context

Alkermes operates in the global biopharmaceutical industry, specifically focusing on neuroscience. The company faces ongoing challenges from generic competition, as evidenced by the INVEGA TRINZA and VUMERITY ANDA litigations, a common trend in the pharmaceutical sector. The expiration of significant royalty streams, such as that for INVEGA SUSTENNA, highlights the evolving landscape of intellectual property and revenue diversification for biopharmaceutical companies. Increased R&D investment in pipeline candidates like Alixorexton reflects the industry's continuous drive for innovation to address unmet patient needs in complex neurological disorders. The discussion of global trade policies and potential tariffs underscores the broader geopolitical and economic factors impacting the global pharmaceutical supply chain and market dynamics.

Comparison to Industry Standards

• NA

Legal Proceedings

• INVEGA TRINZA ANDA Litigation: The U.S. Court of Appeals for the Federal Circuit affirmed the NJ District Court's opinion in favor of Janssen entities regarding patent infringement and validity of the '693 Patent. Mylan Labs filed a petition for panel rehearing or rehearing en banc in May 2025. Alkermes is not a party to this proceeding.
• VUMERITY ANDA Litigation: A confidential settlement agreement was reached on July 21, 2025, granting Zydus a license to commercialize a generic version of VUMERITY in the U.S. from an agreed date prior to patent expiration. The litigation was dismissed.
• Government Matters: The company has received a subpoena and civil investigative demands from U.S. state and federal governmental authorities for documents related to VIVITROL and is cooperating with the investigations.
• Product Liability and Other Legal Proceedings: The company is involved in a product liability case alleging that VIVITROL labeling was inadequate and caused opioid overdose and death, which it intends to vigorously defend. An appeal by Acorda Therapeutics, Inc. seeking additional damages related to an arbitral award was transferred to the U.S. Court of Appeals for the Second Circuit on July 25, 2025.

Stakeholder Impact

• Shareholders: Experienced a decrease in net income and EPS, but saw an increase in cash and cash equivalents. The remaining share repurchase authorization provides potential future value. The positive clinical trial results for Alixorexton and the resolution of VUMERITY litigation offer future growth prospects.
• Employees: The company increased R&D and sales/marketing headcount, indicating continued investment in growth and commercialization efforts.
• Customers: Continued access to proprietary products like VIVITROL, ARISTADA, and LYBALVI, with sales growth in these key products.
• Partners/Licensees: Revenue from Janssen (INVEGA products) was significantly impacted by the expiration of the INVEGA SUSTENNA royalty. The settlement of VUMERITY litigation with Zydus resolves a key patent dispute for Biogen's licensed product.
• Creditors: The company prepaid and terminated its long-term debt in December 2024, improving its balance sheet liquidity.

Next Steps

• Initiation of a Phase 3 program for Alixorexton in narcolepsy.
• Evaluation of the impact of new accounting pronouncements, ASU 2023-09 (Income Tax Disclosures) and ASU 2024-03 (Expense Disaggregation Disclosures), on consolidated financial statements and disclosures.
• Continued cooperation with U.S. state and federal governmental authorities regarding the VIVITROL subpoena and civil investigative demands.
• Vigorous defense in the product liability case alleging VIVITROL caused opioid overdose and death.

Key Dates

Recommendation

Alkermes is navigating a transitional period marked by the expected decline in high-margin royalty revenues due to patent expirations. While this has led to a decrease in overall revenue and net income, the company's core proprietary product sales (VIVITROL, ARISTADA, LYBALVI) are demonstrating robust growth, indicating strong commercial execution. The significant increase in cash from operations and a healthy cash balance provide financial flexibility. Furthermore, the positive Phase 2 results for Alixorexton and the planned advancement to Phase 3 represent a crucial future growth driver. The resolution of the VUMERITY litigation removes a key overhang. Given the mixed financial performance (declining overall revenue but growing proprietary sales) and the strategic investments in the pipeline, a 'hold' recommendation is appropriate. Investors should monitor the continued growth of proprietary products and the progress of Alixorexton's Phase 3 program for future upside, while acknowledging the near-term revenue headwinds from expiring royalties.

Keywords

Biopharmaceutical, Neuroscience, Schizophrenia, Bipolar I disorder, Alcohol dependence, Opioid dependence, Narcolepsy, Idiopathic hypersomnia, VIVITROL, ARISTADA, LYBALVI, Alixorexton, SEC filing, 10-Q, Financial results, Product sales, Royalty revenue, Research and development, Clinical trials, Intellectual property, Share repurchase